Dermata Therapeutics
DRMA
6 hedge funds and large institutions have $110K invested in Dermata Therapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
25% less funds holding
Funds holding: 8 → 6 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
53% less capital invested
Capital invested by funds: $236K → $110K (-$126K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$24.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$15.7K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$14.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$53K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$28.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.9K |
| 4 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
-$19.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$8.82K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Acadian Asset Management
Boston,
Massachusetts
| $79K | +$24.7K | +129 | +34% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $13K | +$15.7K | +82 | New |
|
|
TSS
3
Two Sigma Securities
New York
| $11.8K | +$14.2K | +74 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $5.45K | -$767 | -4 | -11% |
|
5
Wells Fargo
San Francisco,
California
| $744 | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $139 | -$8.82K | -46 | -98% |
|
|
VF
7
Virtu Financial
New York
| – | -$53K | -214 | Closed |
|
|
8
Citadel Advisors
Miami,
Florida
| – | -$28.5K | -115 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20.9K | -84 | Closed |
|
|
HWA
10
HCR Wealth Advisors
Los Angeles,
California
| – | -$19.8K | -80 | Closed |
|
DRMA Hedge Fund Activity: Q3 2023 in Review
6 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics (DRMA) for Q3 2023, worth a combined $110K — down 53% from $236K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of DRMA and 2 opened new positions — a net loss of 2 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Acadian Asset Management, adding an estimated $24.7K. The largest seller was Virtu Financial, exiting entirely with an estimated $53K sold.
- 6 institutional investors held Dermata Therapeutics (DRMA) as of Q3 2023, down from 8 in Q2 2023.
- Funds reported $110K of Dermata Therapeutics stock for Q3 2023, down 53% quarter-over-quarter.
- 2 funds opened new Dermata Therapeutics positions in Q3 2023 and 4 closed out, a net change of -2 holders.
- The largest Dermata Therapeutics buyer in Q3 2023 was Acadian Asset Management, an estimated $24.7K added.
- The largest Dermata Therapeutics seller in Q3 2023 was Virtu Financial, an estimated $53K sold.
Based on aggregated 13F filings for Q3 2023.